TIAA CREF Investment Management LLC boosted its position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 2.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 407,750 shares of the biopharmaceutical company’s stock after buying an additional 10,558 shares during the period. TIAA CREF Investment Management LLC’s holdings in Achillion Pharmaceuticals were worth $1,717,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Teachers Advisors LLC increased its position in shares of Achillion Pharmaceuticals by 42.9% in the first quarter. Teachers Advisors LLC now owns 1,347,858 shares of the biopharmaceutical company’s stock worth $5,674,000 after buying an additional 404,317 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Achillion Pharmaceuticals by 3.8% in the first quarter. Wellington Management Group LLP now owns 1,734,482 shares of the biopharmaceutical company’s stock worth $7,303,000 after buying an additional 64,049 shares in the last quarter. Emory University increased its position in shares of Achillion Pharmaceuticals by 7.1% in the first quarter. Emory University now owns 486,438 shares of the biopharmaceutical company’s stock worth $2,048,000 after buying an additional 32,336 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Achillion Pharmaceuticals during the first quarter worth about $138,000. Finally, Cornerstone Capital Management Holdings LLC. purchased a new position in shares of Achillion Pharmaceuticals during the first quarter worth about $490,000. Institutional investors own 70.83% of the company’s stock.

Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) opened at 4.81 on Thursday. The stock’s 50 day moving average is $4.37 and its 200 day moving average is $4.12. The stock’s market cap is $657.82 million. Achillion Pharmaceuticals, Inc. has a 12 month low of $3.15 and a 12 month high of $9.49.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.16). During the same period in the previous year, the firm earned ($0.14) EPS. Analysts predict that Achillion Pharmaceuticals, Inc. will post ($0.67) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “TIAA CREF Investment Management LLC Purchases 10,558 Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/tiaa-cref-investment-management-llc-purchases-10558-shares-of-achillion-pharmaceuticals-inc-nasdaqachn/1469230.html.

A number of brokerages recently issued reports on ACHN. Robert W. Baird downgraded shares of Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price target for the company. in a research note on Thursday. Maxim Group set a $7.00 price target on shares of Achillion Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday. Chardan Capital decreased their price target on shares of Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating for the company in a research note on Wednesday. BidaskClub downgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 5th. Finally, Zacks Investment Research upgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $8.25.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.